Part:BBa_K2976006
Anti-PD-L1 peptide
Usage and Biology
Anti-PD-L1 peptide selectively binds to programmed death ligand 1 (PD-L1), an immune checkpoint protein that is overexpressed in many cancer cell lines. Recent study has demonstrated that the Mtb-infected macrophages express more PD-L1 than normal ones. Thus, PD-L1 could be a promising target for intracellular Mtb therapy. In 2019 CPU_CHINA project, anti-PD-L1 peptide is displayed on the surface of the exosome to specifically targeting the Mtb-infected macrophages.
Characteristics
Anti-PD-L1 peptide was designed as a fusion protein with lamp2 and HA tag. With the confirmation of HA tag (Fig.1), the expression of anti-PD-L1 was confirmed as well.
For more details, please check out our demonstrate page.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
MIT_MAHE 2020
Summary
Anti-PD-L1 peptide selectively binds to programmed death ligand 1 (PD-L1), an immune checkpoint protein that is overexpressed in many cancer cell lines. Recent study has demonstrated that the Mtb-infected macrophages express more PD-L1 than normal ones. Thus, PD-L1 could be a promising target for intracellular Mtb therapy.
References
1. Liu, H., Zhao, Z., Zhang, L. et al. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. j. immunotherapy cancer 7, 270 (2019). https://doi.org/10.1186/s40425-019-0705-y
| None |